Friday, September 05, 2014 10:26:51 PM
Prices do not change, with or without persistence (as measured on the scale of time on which one is observing), due to news or new information, in of itself. Prices change due to imbalanced anxieties of buyers and sellers driven by their anticipations. Now, it may be fair to say that the latest bit of information causes imbalances in anxieties, and consequently, the whole puzzle is about anticipations, about speculations, about a surmise of the next moment, next minute, next hour, next day, next decade...so on and so forth.
In any case, this new information takes time to disseminate among market participants. And, during this period of dissemination and acceptance of a new perception, prices may or may not trend higher. If you are the first person to acquire and understand this new information, you are said to have a variant perception. If you are the second or third person to realize that there is new information, you are called a trend follower. And if you instinctively fade this perception as it disseminates through the market, you are either called a contrarian, or tigertrader.
A stock’s fundamentals and it's past history are identical for all observers. Yet, the stock and it’s future are perceived uniquely by each. The debate will always continue, since no two minds are same. Some will be correct and others incorrect, but these are inevitably post-trade assessments, which means companies have the opportunity to adopt an industrial-approach to investor growth.
Every buyer does not matter in this equation - the .majority of unique changes in a company’s stock price results from the net purchases of the stock by a limited number of investors who trade in large quantities. Both, current and potential investors can significantly influence the share prices of most companies. So, the stock's company should be aware of who is moving their shares as investors come and go over time, and assess who has the potential to move its stock price in the future.
Because, CYRX is on the OTCBB, the odds are buyers are not going to be active stock-portfolio managers, nor managers of mutual, pension, or hedge funds. Some of the movers of SP could be among the company’s largest current shareholders. Some may be smaller holders who want to increase their ownership. And, some could be potential large players who do not yet own any of the company's stock but could purchase it in large quantities. Cryoport should actively seek investors who have speculated on companies that were in a similar space as Cryoport, or a similar stage of commercialization as Cryoport. Potential movers of the stock could be investors who have bought shares in Cryoport’s upstream or downstream partners and want to invest more broadly in the value chain. And some potential buyers may have an inclination for speculating in companies with the same business model as Cryoport.
Companies cannot look at the market as a monolithic entity that is judging a company's performance in an adversarial way. Instead, they must take both a broad and a granular view of the market. The buyers that will bring a higher valuation to the company's stock come from multiple sources, and they must be identified and courted. Cryoport must take a more structured and rigorous approach to marketing their stock to investors.
or investors might just follow Will Rogers' advice...
"Don't gamble; take all your savings and buy some good stock and hold it till it goes up, then sell it.
If it don't go up, don't buy it."
Recent CYRX News
- Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024 • PR Newswire (US) • 04/30/2024 12:30:00 PM
- Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/12/2024 08:05:00 PM
- Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 • PR Newswire (US) • 02/27/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:42:22 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 05:22:50 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:23:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/21/2023 09:30:37 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/20/2023 05:15:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:19:00 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/15/2023 10:09:12 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 12/15/2023 10:05:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 11:02:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/11/2023 10:09:00 PM
- Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services • PR Newswire (US) • 11/27/2023 01:30:00 PM
- Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express • PR Newswire (US) • 11/16/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:30:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 07:18:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:31:41 PM
- Cryoport Reports Third Quarter 2023 Financial Results • PR Newswire (US) • 11/08/2023 09:05:00 PM
- Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition • PR Newswire (US) • 11/02/2023 12:30:00 PM
- Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023 • PR Newswire (US) • 10/25/2023 12:30:00 PM
- Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF • PR Newswire (US) • 10/12/2023 12:30:00 PM
- Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies • PR Newswire (US) • 10/10/2023 12:30:00 PM
- Be The Match BioTherapies® and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies • PR Newswire (US) • 10/09/2023 08:05:00 PM
- Cryoport Receives 2023 IMAPAC Asia Pacific Cell & Gene Therapy Excellence Award • PR Newswire (US) • 09/14/2023 12:30:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM